GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice

Romera, Irene; Santos, Miriam Rubio-de; Artola, Sara; Fernández, Carmen Suárez; Conget, Ignacio

doi:10.1007/s12325-023-02442-z

Cited by 3 publications

(1 citation statement)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The accumulation of evidence on the benefits of OW GLP-1RAs may not necessarily lead to the optimal use of these drugs in guideline-recommended populations as it is a multifaceted issue extending beyond this. Contributing factors may include clinical barriers (e.g., lack of practical knowledge on the use of drug, fear of adverse effects or injections), patient access barriers (e.g., affordability), and other factors (e.g., inadequate awareness or lower confidence in use among healthcare professionals outside endocrinologists) [ 40 – 42 ]. Addressing these barriers may require collaborative efforts from various stakeholders to implement targeted interventions or policies and ultimately improve patient outcomes.…”

Section: Discussionmentioning

confidence: 99%

Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE)

Tan,

Divino,

Amamoo

et al. 2024

Clin Drug Investig

View full text Add to dashboard Cite

Background The efficacy of once-weekly (OW) glucagon-like peptide-1 receptor agonists (GLP-1RAs) has been established in several trials in people with type 2 diabetes mellitus (T2DM); however, real-world evidence on their effectiveness is limited. This study evaluated the effectiveness of OW GLP-1RA regarding glycemic and weight outcomes, and relative to DPP-4i in a comparator analysis. Methods This observational cohort study evaluated glycated hemoglobin (HbA 1c ) and weight outcomes in people with T2DM with two or more prescription claims for the same OW GLP-1RA using a pre-post study design (including for a semaglutide OW T2DM subgroup, hereafter referred to as semaglutide). Comparator analysis for the same outcome was performed for OW GLP-1RAs versus DPP-4i and semaglutide subgroup versus DPP-4i. A linked patient population from the IQVIA PharMetrics ® Plus database and the Ambulatory Electronic Medical Records (AEMR) database was analyzed using data from January 2017 to April 2022. HbA 1c and weight were assessed at baseline and at the end of the 12-month post-index period. Inverse probability of treatment weighting (IPTW) was used to adjust for imbalances in baseline patient characteristics in the comparator analysis. Results In the pre-post analysis, a greater numerical reduction in HbA 1c and weight was observed for the semaglutide subgroup ( N = 354) relative to the OW GLP-1RA cohort ( N = 921). In the semaglutide subgroup, 52.5% and 34.2% of patients achieved HbA 1c of < 7.0% and ≥ 5% weight loss, respectively. For the comparator analysis, the OW GLP-1RAs ( N = 651) were significantly more effective ( p < 0.001) in reducing HbA 1c (− 1.5% vs. − 1.0%) and weight (− 3.2 kg vs. − 1.0 kg) than the DPP-4is ( N = 431). Similarly, the semaglutide cohort ( N = 251) also displayed more effectiveness ( p < 0.001) in reducing HbA 1c (− 1.7% vs. − 0.9%) and weight (− 4.1 kg vs. − 1.3 kg) than the respective DPP-4i cohort ( N = 417). Patients initiating OW GLP-1RAs, including the semaglutide cohort, were at least twice as likely to achieve HbA 1c and weight outcomes as well as composite outcomes compared with those initiating DPP-4is. Conclusion The study reinforces that OW GLP-1RAs are more effective in glycemic control and weight reduction compared with DPP-4is in people with T2DM in the real-world setting. These findings align with the recommendation in the current guidelines for utilizing glucose-lowering treatment regimens that support weight-management goals in people with T2DM. ...

show abstract

Section: Discussionmentioning

confidence: 99%

Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE)

Tan,

Divino,

Amamoo

et al. 2024

Clin Drug Investig

View full text Add to dashboard Cite

show abstract

Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain

Botana López,

Camafort Babkowski,

Campuzano Ruiz

et al. 2024

Adv Ther

View full text Add to dashboard Cite

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for glycemic control, with many also demonstrating cardiovascular (CV) benefit, in people with type 2 diabetes (T2D). This study aimed to find a consensus on the barriers and strategies for the optimal use of GLP-1 RAs in people with T2D and high CV risk or established cardiovascular disease (CVD) in Spain. Methods: A two-round Delphi survey (53 questions) was conducted among members of four national scientific societies in Spain, including physicians experienced in the management of people with T2D. The degree of consensus was evaluated with a 7-point Likert scale, establishing consensus when ≥ 70% of the panelists agreed (6-7) or disagreed (1-2).

show abstract

Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA

King,

Tan,

Dhopeshwarkar

et al. 2024

BMJ Open Diab Res Care

View full text Add to dashboard Cite

IntroductionThis study aimed to assess recent trends in the US use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) in people with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD), including incident use following newly diagnosed ASCVD.Research design and methodsThis real-world, retrospective observational study used de-identified data from the TriNetX Dataworks–USA network. A longitudinal analysis of cross-sectional data (interval: January 01, 2018 to December 31, 2022) assessed the yearly prevalent use of GLP-1 RA and SGLT2i. A nested cohort study (January 01, 2017 to January 31, 2023) assessed the proportions of patients with T2D newly prescribed GLP-1 RAs and SGLT2is after incident ASCVD diagnosis.ResultsPrevalent use of GLP-1 RA and/or SGLT2i increased from 9.2% of patients in 2018 to 27.1% in 2022, with eligible annual patient numbers ranging from 279,474 to 348,997. GLP-1 RA-alone use rose from 5.2% to 9.9% and SGLT2i-alone use rose from 2.8% to 12.2% over this interval. Incident use of GLP-1 RA and/or SGLT2i within the year following ASCVD diagnosis increased from 5.9% to 17.0% (2018–2022). For GLP-1 RA alone, this increase was from 3.6% to 7.8%, while for SGLT2i alone, it was from 1.8% to 7.0%.ConclusionsUse of GLP-1 RAs/SGLT2is in patients with T2D and ASCVD has increased in recent years in the USA, but remains suboptimal given the prevalence of ASCVD and its high morbidity and mortality.

show abstract

GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice

Cited by 3 publications

References 68 publications

Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE)

Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE)

Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain

Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA

Contact Info

Product

Resources

About